# Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane

> **NCT02728622** · PHASE3 · COMPLETED · sponsor: **Nordic Society of Gynaecological Oncology - Clinical Trials Unit** · enrollment: 241 (actual)

## Conditions studied

- Ovarian Cancer
- Peritoneal Cancer
- Cancer of the Fallopian Tube

## Interventions

- **DRUG:** Tamoxifen
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT02728622
- **Lead sponsor:** Nordic Society of Gynaecological Oncology - Clinical Trials Unit
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2008-01
- **Final completion:** 2009-01
- **Target enrollment:** 241 (ACTUAL)
- **Last updated:** 2016-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02728622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02728622, "Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02728622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*